1.	Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02616, ACNS0822, CDR0000688443, U10CA098543, COG-ACNS0822, NCT01236560
2.	Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: NCI, Other Protocol IDs: ACNS0331, COG-ACNS0331, CDR0000365506, NCT00085735
3.	Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 Sponsor: NCI, Other Protocol IDs: ACNS0334, NCI-2009-00338, COG-ACNS0334, CDR0000483683, U10CA098543, NCT00336024
4.	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: ACNS0332, NCI-2009-00336, COG-ACNS0332, CDR0000511991, U10CA098543, R01CA114567, NCT00392327
5.	Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 1 to 18 Sponsor: NCI, Other Protocol IDs: CDR0000588655, COG-ACCL0431, ACCL0431, NCT00716976
6.	The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients Phase: Phase III Type: Supportive care Status: Active Age: 1 to 21 Sponsor: Other Protocol IDs: 06-08-367, NCT00726934
7.	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: Other Protocol IDs: SJMB03, SJCRH-SJMB03, NCT00085202
8.	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: CPT-SIOP-2009, NCT01014767
9.	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: ACNS0831, NCI-2011-02029, COG-ACNS0831, CDR0000668560, U10CA098543, NCT01096368
10.	Low Dose Versus High Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation Phase: Phase III Type: Supportive care Status: Active Age: 2 to 18 Sponsor: Other Protocol IDs: 1000014713, NCT01135550
11.	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and under Sponsor: NCI, Other Protocol IDs: AEWS1031, NCI-2011-02611, COG-AEWS1031, CDR0000687639, U10CA098543, NCT01231906
12.	A Randomized Study of Antineoplaston Therapy vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 6 months to 17 years Sponsor: Other Protocol IDs: BRI-BT-54, NCT01260103
13.	Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Phase: Phase III Type: Supportive care Status: Active Age: 4 to 18 Sponsor: NCI, Other Protocol IDs: SCUSF 1202, COG-ACCL1032, ACCL1032, NCT01346267
14.	A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225C2301, NCT01708174
15.	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 2 to 21 Sponsor: NCI, Other Protocol IDs: SCUSF 0703, 5U10CA081920-11, NCT01132547
16.	A Phase I/II Study of the Photon Radiosurgery System Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
17.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
18.	Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
19.	A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
20.	New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 3 to 75 Sponsor: Other Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
21.	Vorinostat and Radiation Therapy Followed By Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Pontine Glioma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02600, ACNS0927, U10CA098543, U10CA97452, COG-ACNS0927, NCT01189266
22.	Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 26901-COGLI, NCT01205334
23.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
24.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
25.	Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 17 and under Sponsor: Other Protocol IDs: 2011-0804, NCT01469247